During the past quarter decade, the rapid expansion health information through the institution of electronic health records, the implementation new technologies for large-scale generation of multi-omic and imaging data, and development of new statistical and computational methodologies for cancer research has led to a recognition of the critical need for participation of quantitative scientists in the research process and a higher standard for what constitutes acceptable scientific evidence in a study. The GI SPORE will conduct large-scale studies and generate substantial quantities of complex biological and biomedical data. Ensuring that the SOPRE's research projects arrive at robust and statistically significant conclusions. The Biostatistics and Bioinformatics Core includes leading quantitative research scientists who will work with SPORE personnel to assure that the research carried out meets the prevailing and emerging research standards and adapts as new technologies develop and are introduced into the scientific research program. This support will be provided by establishing, maintaining, and supporting collaborative relationships that will ensure that Core members are integrated members of the research teams and provide appropriate statistical and computational support for all GI cancer SPORE investigators. This will include consultation and collaboration on all aspects of study design, database development and quality control, and analysis and interpretation of data.
The Biostatistics and Bioinformatics Core will provide support for the research mission of the GI SPORE by assisting the members of the Programs and other Cores in the design of their experiments and the analysis and interpretation of the resulting data. The Core personnel represent leading experts in biostatistics and bioinformatics and will use modern, advanced methods to assure the conclusions emerging from the SPORE are robustly supported by the underlying data.
Cao, Yin; Wu, Kana; Mehta, Raaj et al. (2018) Long-term use of antibiotics and risk of colorectal adenoma. Gut 67:672-678 |
Barry, Joseph D; Fagny, Maud; Paulson, Joseph N et al. (2018) Histopathological Image QTL Discovery of Immune Infiltration Variants. iScience 5:80-89 |
Danai, Laura V; Babic, Ana; Rosenthal, Michael H et al. (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600-604 |
Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749 |
Corcoran, Ryan B; André, Thierry; Atreya, Chloe E et al. (2018) Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov 8:428-443 |
Song, Mingyang; Wu, Kana; Meyerhardt, Jeffrey A et al. (2018) Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol 4:71-79 |
Babic, A; Schnure, N; Neupane, N P et al. (2018) Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 9:145 |
Lopes-Ramos, Camila M; Kuijjer, Marieke L; Ogino, Shuji et al. (2018) Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. Cancer Res 78:5538-5547 |
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230 |
Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822 |
Showing the most recent 10 out of 590 publications